YUQ A1007
Alternative Names: YUQ-A-1007Latest Information Update: 31 Mar 2025
At a glance
- Originator AllianThera Biopharma
- Class Anti-inflammatories
- Mechanism of Action Aryl hydrocarbon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 22 Feb 2025 Allianthera Biopharmaceuticals plans a phase I trial for Inflammatory bowel diseases (In volunteers) (PO) in February 2025 (NCT06835296)
- 19 Feb 2025 Preclinical trials in Inflammatory bowel diseases in China (PO) prior to February 2025
- 18 Sep 2024 AllianThera Biopharma has patents pending for 'Novel modulators of the aryl hydrocarbon receptor and methods of use thereof' in Europe